Related Experiment Videos
Diagnosis and management of primary pulmonary hypertension
1Institute of Cardiovascular Diseases, Madras Medical Mission, Chennai.
Insights
Pediatric pulmonary hypertension, often primary (PPH), progresses rapidly with poor survival. Vasodilators, anticoagulation, and septostomy offer treatment options, with lung transplantation as a future possibility.
Area of Science:
- Pediatric Cardiology
- Pulmonology
- Vascular Biology
Background:
- Pediatric pulmonary hypertension (PPH) can be idiopathic or secondary to congenital heart defects.
- PPH progresses rapidly in children, with a mean survival of 2-3 years post-diagnosis.
- Histological changes include medial hypertrophy and plexiform lesions in pulmonary vasculature, leading to increased pulmonary artery pressure and right ventricular dysfunction.
Purpose of the Study:
- To review the pathophysiology, clinical presentation, and current management strategies for pediatric pulmonary hypertension.
- To highlight the rapid progression and poor prognosis of PPH in children compared to adults.
- To discuss emerging therapeutic options and future directions in managing this condition.
Main Methods:
- Literature review of pediatric pulmonary hypertension.
- Analysis of histological changes in pulmonary vasculature.
- Summary of clinical presentations and diagnostic considerations.
- Evaluation of current and potential treatment modalities.
Main Results:
- Over 50% of children with PPH benefit from vasodilators, including calcium channel blockers.
- Inhaled nitric oxide and intravenous prostacyclin infusion are options for non-responders.
- Anticoagulation and atrial septostomy may improve survival in select cases.
Conclusions:
- Pediatric pulmonary hypertension requires prompt diagnosis and management.
- A multi-faceted approach involving vasodilators, anticoagulation, and potentially surgical interventions is crucial.
- Lung transplantation represents a potential future therapy for refractory cases.
Abstract:
Pulmonary arterial hypertension in children can occur secondary to shunt lesion like ventricular septal defect, patent ductus arteriosus or it may be idiopathic, the so called primary pulmonary hypertension (PPH). The progression of PPH is usually rapid in children as compared to adults and the mean survival is 2-3 years after the diagnosis is made. Histological changes in the form of medical muscular hypertrophy, intinal hyperplasia and later angiomatous, plexiform lesions occur in pulmonary vasculature. The pulmonary vasculature normally is a high flow, low resistance circuit and allows large blood flow without marked increase in pulmonary arterial pressure. However, with prolonged increased flow or any other vasoconstrictor stimulus, histological changes start occurring in the pulmonary bed resulting in increasing pressure in pulmonary artery. Right ventricular hypertension follows resulting in right ventricular hyypertrophy and later dysfunction. Life threatening arrhythmias may result in sudden death in some of these patients. Clinical presentation is in the form of exertional dyspnoea with syncope at times. Over 50% of children with PPH are helped by vasodilators. They may be treated with calcium channel blockers (e.g. nifedipine, dose titrated to blood pressure) orally. Those not responding to oral vasodilators can be put on chronic inhaled nitric oxide or continuous intravenous prostacyclin infusion. Chronic anticoagulation therapy may also increase survival. In symptomatic cases, blade/balloon atrial septostomy may increase survival in patients of PPH with intact atrial sptum. For children not responding to medical therapy, lung transplantation may be the answer in near future.